INKT

MiNK Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website minktherapeutics.com
Employees(FY) 37
ISIN US6036932019

Performance

-6.06%

+45.4%

+27.05%

-0.88%

+31.44%

YTD

+5.9%

Profile

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It's product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Advanced Technical Analysis

Technical Analysis of INKT 2025-01-31

The stock exhibits a strong bullish sentiment with a Moving Average Score of 96 and a Technical Score of 90, indicating robust upward momentum. While the Oscillators Score of 56 suggests a neutral stance, the overall indicators point towards a favorable outlook for the stock.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of INKT

Stock Rank

Recent News & Updates

2025-01-23 01:13
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI(Globenewswire)
2024-12-17 20:45
MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting(Globenewswire)
2024-11-14 13:17
Q3 2024 Mink Therapeutics Inc Earnings Call(Yahoo Finance)
2024-11-14 13:09
MiNK Therapeutics Inc (INKT) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...(Yahoo Finance)
2024-11-13 18:00
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update(Globenewswire)
2024-11-10 18:30
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report(Globenewswire)
2024-11-06 21:00
MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024(Globenewswire)
2024-10-30 21:15
MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors(Globenewswire)
2024-10-09 06:15
MiNK Therapeutics Inc (INKT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...(Yahoo Finance)
2024-10-07 19:30
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors(Globenewswire)
2024-10-03 21:10
MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024(Globenewswire)
2024-09-02 19:30
MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference(Globenewswire)
2024-08-12 19:00
MiNK Reports Second Quarter 2024 Results and Business Update(Globenewswire)
2024-07-31 19:30
MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report(Globenewswire)
2024-07-30 19:30
MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement(Globenewswire)
2024-07-11 00:00
MiNK Therapeutics, Inc. (INKT) Upgraded to Strong Buy: Here's What You Should Know(Zacks)
2024-06-04 19:30
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting(Globenewswire)
2024-05-21 19:30
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting(Globenewswire)
2024-05-14 15:04
MiNK Therapeutics Inc (INKT) Q1 2024 Earnings Call Transcript Highlights: Strategic Reductions ...(Yahoo Finance)
2024-05-13 23:52
INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q1 2024(Investorplace)
2024-05-13 19:30
MiNK Reports First Quarter 2024 Results(Globenewswire)
2024-05-12 19:30
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer(Globenewswire)
2024-04-29 19:30
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report(Globenewswire)
2024-04-08 00:00
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR(Globenewswire)
2024-03-25 00:00
All You Need to Know About MiNK Therapeutics, Inc. (INKT) Rating Upgrade to Buy(Zacks)
2024-03-22 01:25
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript(Insidermonkey)
2024-03-21 11:06
Q4 2023 Mink Therapeutics Inc Earnings Call(Yahoo Finance)
2024-03-20 23:53
INKT Stock Earnings: MiNK Therapeutics Misses EPS for Q4 2023(Investorplace)
2024-03-20 19:00
MiNK Reports Fourth Quarter and Year-End 2023 Results(Globenewswire)
2024-03-06 18:30
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report(Globenewswire)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.